Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Clinical trial NCT05239624 · RECRUITING

Trial details

NCT number: NCT05239624
Sponsor: Memorial Sloan Kettering Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Urothelial Carcinoma

Start date: 2022-06-02
Primary completion: 2027-06-01
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.